ABSTRACT Aims/Introduction: Diabetic nephropathy is one of the leading causes of end-stage renal disease. Unfortunately, reliable surrogate markers for predicting the prognostic outcome of diabetic nephropathy are as yet absent. In order to find new markers in predicting the progression of diabetic nephropathy, we carried out a prospective study by investigating the correlation between serum metabolites and the annual change of estimated glomerular filtration rate (eGFR). Materials and Methods: From September 2013 to September 2015, 52 diabetes patients at various stages of chronic kidney disease were enrolled. While serum levels of 175 metabolites were measured by AbsoluteIDQ TM p180 kit, only those with a significant difference in advancing chronic kidney disease stages were selected. After then, serial renal function change of these patients was followed up for 12 months, the outcome of renal function with each selected metabolite was compared according to the occurrence of a rapid decline (sustained annual decrement rate ≥5%) of eGFR. Results: A total of 26 metabolites were found to be significantly associated with the severity of chronic kidney disease. Tryptophan (Trp) showed a significant association with the event of rapid decline in eGFR (P = 0.036). Serum concentration of Trp <44.20 lmol/L showed the most valuable predictive value with 55.6% sensitivity and 87% specificity. Conclusions: A lower level of Trp, especially <44.20 lmol/L, was related to a rapid decline in eGFR. Accordingly, Trp might be regarded as a potential prognostic marker for diabetic nephropathy.
INTRODUCTION
Diabetes mellitus has become a worldwide health issue, with an ever-increasing incidence in recent years owing to highly developed socioeconomic status and sedentary lifestyles 1 . Complications of diabetes mellitus, such as diabetic nephropathy (DN), could increase all-cause morbidities and mortalities even under intensive blood sugar control, and indeed, DN is one of the leading causes of end-stage renal disease (ESRD) globally 2 . As a long-term complication of diabetes, DN has been reported to occur in 5-40% of patients with type 1 or type 2 diabetes mellitus 3, 4 . Once nephropathy progresses, approximately 20-40% of patients inevitably develop ESRD.
DN might have plethoric clinical manifestations, such as albuminuria, elevated blood pressure and eventually diminished renal function. It is a great challenge to predict the risk of disease progression among patients with DN. Currently, the estimated glomerular filtration rate (eGFR) is the most frequently used method to measure and categorize renal function, which is calculated based on the serum creatinine level, age, race and sex. Accordingly, deterioration of renal function can be divided into five stages based on the change of eGFR. Nevertheless, limited use of eGFR exists clinically; for example, renal hyperfiltrationrelated high eGFR would underestimate the progression of DN 5 ; furthermore, the accuracy of eGFR in advanced kidney dysfunction has been questioned 6 ; and most importantly, the exact rate of renal function deterioration is seldom predictable by eGFR.
In addition to the alteration of eGFR, DN frequently leads to changes in many metabolites, as that kidneys are not only characterized by high efficiency of excretory and absorptive functions, but are also responsible for rapid protein synthesis and amino acid oxidation 7 . The metabolism of biomolecules thus could fluctuate even in the early stages of DN. Thanks to the recent rapid development of proteomic techniques, metabolized peptides can be identified in tissues 8 and various biological entities 9 . In our interest, the metabolic approach shows a significant relationship between diabetes mellitus and specific metabolites, which shows changes in sugar, amino acids and lipid metabolism 10 . As metabolomics is the latest development in omic technology providing unbiased identification and quantification of small molecules in biological fluids, this approach can complement the proteomic assay to predict the outcome of DN with high sensitivity and specificity.
In the present study, we analyzed the plasma metabolites in patients at different stages of CKD to explore any association between the concentration of serum metabolites and degeneration of renal function. The aim of the present study was to investigate the changes in metabolites at various stages of CKD, and most importantly, to use these metabolites as potentially predictive surrogate markers for DN.
MATERIALS AND METHODS

Patients
With informed consent approved by the institutional review board of Chang Gung Memorial Hospital (IRB no. 104-6411C), we recruited participants at various stages of CKD for monitoring renal function change of type 2 diabetes from September 2013 to September 2015. We included clinically stable patients aged >18 years with regular follow up at Chang Gung Memorial Hospital, Taoyuan City, Taiwan. Patients with acute inflammatory diseases; admitted to a hospital in the past 2 months and/or during the follow-up periods; and lost to regular follow up were excluded. The sample size required for predicting renal function change by metabolomics in the present study was not estimated, because of the scarcity of previous reports. The primary end-point was the occurrence of a rapid decline in renal function in 12 months, with treatment adjusted according to the local guidelines. Finally, a total of 52 patients fulfilling the criteria and able to complete an at least 1 year of follow up were included (Table 1 , respectively. Albuminuria was measured by spot urine albumin and creatinine ratio (UACR). All patients except two were subsequently followed up, and their laboratory data were obtained from our hospital for at least 12 months. All blood samples for metabolomic study were collected in the early morning after overnight fasting. Patients were divided into five groups according to their initial CKD stages. At the end of follow up, the change of Values are presented as mean -standard deviation or n (%). The ANOVA was used for continuous variables; the v eGFR was expressed as the percentage change after comparison with the initial status. A rapid decline of eGFR was defined as a >5% annual decrement according to the previous reports 13, 14 .
Metabolomic Approach
A targeted quantitative metabolomic approach was used in combination with liquid chromatography-tandem mass spectrometry assay and direct flow injection assay (AbsoluteIDQ TM 180 kit; Biocrates Life Science, Innsbruck, Austria) for the metabolomic analyses of the samples. This kit was designed to be used with triplequad mass spectrometry, and allows identification and quantification of more than 180 metabolites. The assay was carried out by using the Waters Acquity Xevo TQ-S (Waters Corp., Milford and Beverly, MA, USA) instrument according to the manufacturer's instructions. Briefly, the samples were thawed, vortexmixed and centrifuged at 13,000 g. In total, 10 lL of sample supernatant was loaded on a filter paper on top of the kit and dried under nitrogen flow. Furthermore, 20 lL of 5% phenyl isothiocyanate was added for derivatization. After a 20-min incubation, the filter spots were dried under nitrogen flow for 45 min. By using 300 lL of methanol containing 5 mmol/L ammonium acetate as extraction solvent, the extracts were obtained in a 96-well plate by centrifugation. Subsequently, the extracts were delivered to liquid chromatography-tandem mass spectrometry for analysis. In total, 175 known small-molecule metabolites were simultaneously quantified based on multiple reaction monitoring. The metabolomics dataset contained 40 acylcarnitine, 21 amino acids, 15 biogenic amines, 14 sphingomyelins and 85 glycerophospholipids. Data were analyzed using a web-based server MetaboAnalyst (www.metaboanalyst.ca ) to find variables that were correlated across the samples.
Statistical Analysis
Continuous data are presented as mean -standard deviation. The association between the initial CKD staging and metabolites was examined using Spearman's rank correlation. All metabolites were corrected for initial CKD stage and plasma concentration by the Kruskal-Wallis one-way ANOVA. Serum concentration of each metabolite-related initial stage of CKD was compared with the occurrence of a rapid decline in eGFR by univariate binary logistic regression. Multivariate binary logistic regression was carried our to clarify the interactions between each metabolite, and to adjust other possible confounding factors. The receiver operating characteristic curve and Youden Index were carried out to identify the most predictive concentration of the metabolite. All data were analyzed by using the Statistical Package for Social Sciences (SPSS version 19; SPSS Inc., Chicago, IL, USA).
RESULTS
In total, 52 patients (26 men and 26 women) participated in the present study (Table 1 ). All except two patients were followed up for >12 months. Patients included in this study had a mean age of 56.4 -14.4 years, with mean duration of diabetes mellitus of 11.0 -8.5 years. Baseline eGFR was 73 -37 mL/ min/1.73 m 2 , and UACR was 709.1 -1603.4 mg/g. The average glycated hemoglobin level was 7.7 -1.6%. Approximately 73% (n = 38) of the patients had hypertension, and 31 of these patients received angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker. Of the 52 patients, 11 experienced coronary artery disease, and eight had a previous cerebral vascular accident.
Patients were separated into five groups according to initial CKD stages (18 in group 1, 15 in group 2, 12 in group 3, 3 in group 4 and 4 in group 5). Patients with advanced CKD stage were noted to be significantly older (P = 0.001) and to have a longer diabetes mellitus duration (P = 0.036). Elevated UACR (P = 0.004) and decreased hemoglobin (P = 0.002) showed a significant association with CKD stage, and indicated the severity of DN. No obvious differences were found in body mass index, prevalence of hypertension and the use of angiotensinconverting enzyme inhibitor or angiotensin II receptor blocker among the five groups.
After a 12-month follow up, the average eGFR became 70 -40 mL/min/1.73 m 2 , without a significant difference as compared with the initial eGFR (P = 0.055, Wilcoxon signed ranks test). Eventually, 52% (n = 27) of the patients had a rapid decline in eGFR (11/18 in group 1; 5/15 in group 2; 7/12 in group 3; 1/3 in group 4; and 3/4 in group 5).
Out of the 175 metabolites that were analyzed, significant differences were observed in 26 metabolites based on the Kruskal-Wallis one-way ANOVA (Table 2) . Among these metabolites, C14, C14:1-OH, C14:2-OH, C16-OH, C16:1, C16:1-OH, C16:2, C16:2-OH, C3-OH, C4, C4:1, C5-DC/C6: OH, C5:1, C7-DC, arginine, aspartate, citrulline, creatinine, kynurenine, t4-OH-Pro and symmetric dimethylarginine levels increased with the progression of kidney dysfunction; whereas serine (Ser), tryptophan (Trp), tyrosine (Tyr), valine (Val) and PC aa C38:6 levels decreased with the progression of kidney dysfunction (Figures 1 and 2) . Creatinine was excluded in further analysis, because it is a known marker for renal function.
After comparing the aforementioned metabolites with occurrence of rapid eGFR decline, Trp was the only metabolite showing s significant difference (P = 0.036; Table 3 ) by multivariate analysis. Once again, Trp remained significantly associated with rapid eGFR decline after adjusted to confounding factors including sex, age, duration of diabetes, glycated hemoglobin, hemoglobin, UACR and use of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker (Table 4) . To detect the optimal cut-point of Trp on predicting DN progression, receiver operating characteristic curve analysis and the Youden Index were applied, with a cut-off value of 42.20 lmol/L showing a sensitivity of 55.6% and a specificity of 87%, respectively (Figure 3 ESRD, and the risk for cardiovascular morbidity and mortality has concomitantly increased. Although eGFR sensitively reflects the renal function at the time of the test, it seldom predicts the exact rate of DN deteriorations when the serum creatinine levels have risen already. As expected, a more effective method that can precisely predict and prevent the development and progression of DN at earlier stages might become a cornerstone of diabetes treatment.
In the present study, we found 26 metabolites significantly associated with eGFR change; among which, levels of 21 metabolites (C14, C14:1-OH, C14:2-OH, C16-OH, C16:1, C16:1-OH, C16:2, C16:2-OH, C3-OH, C4, C4:1, C5-DC/C6: OH, C5:1, C7-DC, arginine, aspartate, citrulline, creatinine, kynurenine, t4-OH-Pro and symmetric dimethylarginine) increased, and levels of five metabolites (serine, Trp, Tyr, Val and PC aa C38:6) decreased in patients with DN. C14, C14:1-OH, C14:2-OH, C16-OH, C16:1, C16:1-OH, C16:2, C16:2-OH, C3-OH, C4, C4:1, C5-DC/C6:OH, C5:1 and C7-DC are acylcarnitines; arginine, aspartate, citrulline, serine, Trp, Tyr and Val are amino acids; creatinine, kynurenine, t4-OH-Pro and symmetric dimethylarginine are biogenic amines; whereas PC aa C38:6 are glycerophospholipids. Acylcarnitines are filtered through the kidney, and nearly 75% are excreted into urine; as a consequence, serum acylcarnitines increased in patients with CKD 15 when the renal excretory function was progressively lost, and mainly short-chain acylcarnitine levels were significantly changed in advanced DN 16 . Pathophysiologically, DN is a result of a complex interaction between metabolic, inflammatory and hemodynamic change. Concomitantly, reactive oxygen species produced during the series of the aforementioned reactions precipitate the development of DN 17, 18 . It has been reported that several energy pathway-related metabolites including fatty acids, citrate cycle intermediates, glycerophospholipids, 3-indoxyl sulfate and Trp act as potential biomarkers for DN 19 . Other studies have additionally shown decreased concentration of the serum branched amino acids and Trp in experimental studies, and in patients with advanced CKD 7, 20, 21 . In the present study, the changes of amino acids, especially Trp (an essential non-polar aromatic amino acid that contains a side chain) showed a significant association with rapid decline in eGFR. The present study is the first study to show direct evidence of the prognostic value of Trp in DN.
Whether a decreased Trp level simply reflects deteriorating renal function or whether Trp itself contributes as an exacerbating and/or protective factor remains controversial. For instance, a recent finding of significantly increased chlorination and oxidation of Trp residues in the non-collagenous hexamer (a key connection module of collagen IV networks) of diabetes patients suggests that Trp might be involved in renal oxidation . Furthermore, indoxyl sulfate, a metabolite of Trp, has been shown to play an important role in renal function regression 23 . After digestion, dietary Trp could be changed to indole by the microbiota in the colon, and further metabolized to indoxyl sulfate in the liver.
Accumulation of indoxyl sulfate occurred in patients with CKD owing to the decreased function of secretion 24 . An elevated concentration of indoxyl sulfate could lead to increased oxidative stress 25 , increased cellular senescence by activation of nuclear factor-jB 26 and increased tubulointerstitial fibrosis by decreasing the expression of klotho, an anti-aging gene 27 . 
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We hypothesize that disequilibrium in oxidative and antioxidative circumstances as a result of altered enzyme activities, Trp residual chlorination and oxidation-induced structural instability of collagen hexamer, and the deposition of uremic toxins, such as indoxyl sulfate, are possible etiological factors to precipitate renal function deterioration. However, several limitations exist in the present study; first of all, serum concentration of the oxidative metabolites and indoxyl sulfate have not been evaluated in this study; thus, direct evidence to support the association between Trp concentration, renal oxidative stress and deterioration of renal function is lacking. Second, although studies showed that function of the kynurenine pathway reveals a potential value to predict chronic transplant dysfunction early in patients that received a renal allograft 28 , it did not show a significant difference (P = 0.589) in the rapid decline of eGFR in the present study. One possible mechanism is that the four kynurenine metabolizing enzymes (kynurenine formamidase, kynureninase, 3-hydroxyanthranilate dioxygenase and kynurenine aminotransferase) might not be equally affected by renal function impairment [29] [30] [31] . Third, as an essential amino acid, the daily intake of Trp was not fully quantified in this examination. Variation might be observed if extremely high or low protein intake occurs. Fourth, a relatively small sample size with a majority in the early stage of CKD was noticed in the present study. All patients received just 12 months of follow up. A prolonged follow-up period with an expanded patient number would have made the present result stronger. Finally, we acknowledged that increased hemoglobin turnover might contribute to lower glycated hemoglobin in advanced CKD and mislead the clinical judgment; however, In order to evaluate the predictive value of the indicated metabolites in rapid progression of renal function, the serum concentration of each metabolite was compared between diabetes patients with an estimated glomerular filtration rate annual decrease rate ≥5% to those <5% by binary logistic regression. Multivariate logistic regression was carried out to exclude the interaction of each metabolite. tryptophan (Trp) showed a significant association (P = 0.036) with rapid decline in estimated glomerular filtration rate. *P < 0.05. Arg, arginine; Asp, aspartate; Cit, citrulline; Kyn, kynurenine; SDMA, symmetric dimethylarginine; Ser, serine; Tyr, tyrosine; Val, valine.
an alternative method, such as glycoalbumin, was not available in this hospital.
In conclusion, among the 175 metabolites screened in the present study, 26 metabolites were affected by renal function change in type 2 diabetes. A lower level of Trp (<44.2 lmol/L) might be regarded as a potential surrogate prognostic marker for diabetic nephropathy. 
